Gilead announces latest data in ongoing HIV cure research program
Gilead reported results from studies of toll-like receptor 7 agonists as part of an HIV cure program. The Phase 1 and preclinical study results demonstrate the TLR7 agonists vesatolimod (GS-9620) and GS-986 can induce immune activation and TLR7 agonists can potentially lead to viral remission. July 23, 2019